Erasca to Supply ERAS-0015 in Phase I/II MTAP-Deleted Cancer Combo Trial
Erasca’s pan-RAS molecular glue ERAS-0015 will be combined with Tango Therapeutics’ MTAP-deleted selective PRMT5 inhibitor vopimetostat in a phase I/II clinical trial targeting MTAP-deleted pancreatic cancer and NSCLC. Under the non-exclusive agreement, Erasca will supply ERAS-0015 at no cost while Tango sponsors the study.
1. Collaboration Agreement Details
Erasca and Tango Therapeutics entered a non-exclusive collaboration to evaluate ERAS-0015 in combination with vopimetostat. Erasca will provide ERAS-0015 at no cost, while Tango will sponsor and manage the phase I/II study infrastructure and patient enrollment.
2. Trial Design and Objectives
The joint study will assess safety, tolerability and preliminary efficacy of the combination in MTAP-deleted RAS-mutant pancreatic cancer and non-small cell lung cancer. Dual inhibition of the RAS pathway and PRMT5 aims to enhance tumor suppression and improve response durability.
3. ERAS-0015 Clinical Progress
ERAS-0015 is currently in the phase I AURORAS-1 study for RAS-mutant solid tumors, showing initial responses at low dose levels across multiple tumor types. These early activity signals support its potential synergy with vopimetostat.
4. Commercial Rights and Future Outlook
Under the agreement, both companies retain rights to their respective assets for future commercialization. Positive trial outcomes could strengthen Erasca’s pipeline and valuation as it advances ERAS-0015 into later-stage development.